Filtered By:
Specialty: Neurology
Condition: Multiple Sclerosis
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
The emerging role of FTY720 as a sphingosine 1 âphosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms
Three important mechanisms for neuroprotective effects of FTY720 have been described. Functional antagonistic, functional agonistic and receptor-independent mechanisms. Here, we review these mechanisms in more details and describe animal model and in clinical trial studies AbstractFinding novel and effective drugs for the treatment of ischemic stroke is warranted because there is not a definitive treatment for this prevalent disease. Due to the relevance between the sphingosine 1-phosphate (S1P) receptor and several neurological diseases including ischemic stroke, it seems that fingolimod (FTY720), as an agonist of S1P rec...
Source: Brain and Behavior - May 10, 2021 Category: Neurology Authors: Maryam Naseh,
Jafar Vatanparast,
Ali Rafati,
Mahnaz Bayat,
Masoud Haghani Tags: REVIEW Source Type: research
